This volume is the third in the series devoted to Antibiotics initiated by Springer Verlag in 1967. The first two volumes were devoted to the Mode of Action of Antibiotics and Biogenesis, respectively and were received graciously. During the intervening years these two works have been used often by research workers and students alike and have been quoted extensively. Although a number of other excellent treatises on antibiotics have appeared, the Springer series has set a standard for thoroughness and quality that meets the need of the scientific community. It is against this background that the present Editors set about the preparation of a third volume in the Series on Antibiotics. Since the appearance of Volume I, also dealing with Mechanism of Action, tremendous strides have been made in the depth and breadth of our knowledge of molecular biology, microbial chemistry and molecular pharmacology and of their direct application to studies on the mode of action of drugs. The field of molecular biology itself was in its relative infancy during the preceding decade and the unique role played by many anti biotics in the development of our understanding of nucleic acid synthesis and function and its relationship to protein synthesis and cell physiology has led rapidly to a very precise, understanding of how many of these same antibiotics inhibit susceptible cells.

Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature

When Antibiotics I was published in 1967, the teleological view was held by some that" antibiotics" were substances elaborated by certain microorgan isms for the purpose of competing with other microorganisms for survival in mixed ecological environments. However, not only had J. EHRLICH and his associates shown 15 years earlier that chloramphenicol was produced by Strepto myces venezuelae in cultures of sterilized soils but not in parallel cultures of the same soils which were not sterilized, but operationally, the search for anti cancer antibiotics was actively under way (Antibiotics I reporting on numerous such substances), although the concept of antibiosis could not logically justify such undertakings. This editor hesitates to accept the use of the term "antibiotic" for anti microbial agents of non microbiological origins which is sometimes encountered, but neither does he subscribe to the view that antibiotics are in some fundamental manner different from chemotherapeutic substances of other origins. Modes and mechanisms of action of chemotherapeutic compounds are not systematic functions of their origins nor of the taxonomical position of the target organisms. Consequently, in the selection of topics for Antibiotics III (published in 1975), synthetic drugs and natural products of higher plants (alkaloids) were represented, along with antibiotics in the strict sense of the definition. We now present Antibiotics V, for whose assembly the same selection criteria were applied as for Antibiotics Ill. The aggregate length of the contributions rendered it impractical to place the entire text between the covers of one book.

Metal–organic frameworks (MOFs) are porous crystalline polymers con­structed by metal sites and organic building blocks. Since the discovery of MOFs in the 1990s, they have received tremendous research attention for various applications due to their high surface area, controllable mor­phology, tunable chemical properties, and multifunctionalities, including MOFs as precursors and self-sacrificing templates for synthesizing metal oxides, heteroatom-doped carbons, metal-atoms encapsulated carbons, and others. Thus, awareness and knowledge about MOFs and their derived nanomaterials with conceptual understanding are essential for the advanced material community. This breakthrough new volume aims to explore down-to-earth applications in fields such as bio­medical, environmental, energy, and electronics. This book provides an overview of the structural and fundamental properties, synthesis strate­gies, and versatile applications of MOFs and their derived nanomaterials. It gives an updated and comprehensive account of the research in the field of MOFs and their derived nanomaterials. Whether as a reference for industry professionals and nanotechnologists or for use in the classroom for graduate and postgraduate students, faculty members, and research and development specialists working in the area of inorganic chemistry, materials science, and chemical engineering, this is a must-have for any library.

Implement the most current science and practice in antimicrobial research. Now, find the newest approaches for evaluating the activity, mechanisms of action, and bacterial resistance to antibiotics with this completely updated, landmark reference. Turn to this comprehensive reference for groundbreaking evidence on the molecular link between chemical disinfectants, sterilants, and antibiotics. On the latest methods for detecting antibacterial resistance genes in the clinical laboratory, and antivirogram use to select the most active antiviral components against your patient's HIV.